Inovio Pharmaceuticals Statistics
Total Valuation
INO has a market cap or net worth of $256.89 million. The enterprise value is $215.81 million.
| Market Cap | 256.89M |
| Enterprise Value | 215.81M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
INO has 179.64 million shares outstanding. The number of shares has increased by 100.45% in one year.
| Current Share Class | 179.64M |
| Shares Outstanding | 179.64M |
| Shares Change (YoY) | +100.45% |
| Shares Change (QoQ) | +20.85% |
| Owned by Insiders (%) | 0.22% |
| Owned by Institutions (%) | 29.65% |
| Float | 179.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 859.45 |
| Forward PS | 6.08 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 722.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.57
| Current Ratio | 0.57 |
| Quick Ratio | 0.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -74.87% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 264.49% |
| Weighted Average Cost of Capital (WACC) | 13.36% |
| Revenue Per Employee | $2,669 |
| Profits Per Employee | -$635,135 |
| Employee Count | 112 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.04% in the last 52 weeks. The beta is 1.73, so INO's price volatility has been higher than the market average.
| Beta (5Y) | 1.73 |
| 52-Week Price Change | -27.04% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 55.26 |
| Average Volume (20 Days) | 27,427,876 |
Short Selling Information
The latest short interest is 22.10 million, so 12.30% of the outstanding shares have been sold short.
| Short Interest | 22.10M |
| Short Previous Month | 21.30M |
| Short % of Shares Out | 12.30% |
| Short % of Float | 12.33% |
| Short Ratio (days to cover) | 2.91 |
Income Statement
In the last 12 months, INO had revenue of $298,901 and -$71.14 million in losses. Loss per share was -$0.91.
| Revenue | 298,901 |
| Gross Profit | -53.91M |
| Operating Income | -77.58M |
| Pretax Income | -71.14M |
| Net Income | -71.14M |
| EBITDA | -76.27M |
| EBIT | -77.58M |
| Loss Per Share | -$0.91 |
Balance Sheet
The company has $48.36 million in cash and $7.28 million in debt, with a net cash position of $41.08 million or $0.23 per share.
| Cash & Cash Equivalents | 48.36M |
| Total Debt | 7.28M |
| Net Cash | 41.08M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | -33.92M |
| Book Value Per Share | -0.18 |
| Working Capital | -38.03M |
Cash Flow
In the last 12 months, operating cash flow was -$74.28 million and capital expenditures -$127,444, giving a free cash flow of -$74.41 million.
| Operating Cash Flow | -74.28M |
| Capital Expenditures | -127,444 |
| Depreciation & Amortization | 1.30M |
| Net Borrowing | n/a |
| Free Cash Flow | -74.41M |
| FCF Per Share | -$0.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | -25,953.76% |
| Pretax Margin | -23,798.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -100.45% |
| Shareholder Yield | -100.45% |
| Earnings Yield | -63.85% |
| FCF Yield | -28.97% |
Analyst Forecast
The average price target for INO is $6.33, which is 342.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.33 |
| Price Target Difference | 342.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 1,212.97% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on January 25, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jan 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |